The Trump administration's struggle to seat its science-related nominees has intensified on two fronts at once: it has effectively abandoned its FDA nominee, while the Senate scrapped the vote on its pick to lead the National Science Foundation.

Both posts carry significant leverage. The Food and Drug Administration gates drug and device approvals affecting industry and millions of patients; the National Science Foundation is the central channel for federally funded basic research at US universities.

An abandoned or postponed nominee leaves a key agency without confirmed leadership, extending the time before an installed team can put its policy into effect.